FMC Launches Board Review of Crop-Chem Portfolio, May Sell Assets to Cut $1B Debt

Board Authorizes Strategic Review to Reposition FMC's Crop-Chem Platform

FMC Corporation is launching a board-authorized review of strategic options, including a possible sale, as it seeks to unlock shareholder value and better position its crop-protection and seed-treatment portfolios for long-term growth. The company says the review is in a preliminary stage and may or may not result in a transaction. Management stresses it will continue executing a set of operational priorities while the board evaluates alternatives.

Central to FMC's plan is strengthening the balance sheet with a targeted $1.0 billion of debt paydown expected to come from asset sales and licensing agreements, and the previously announced sale of its India commercial business. The company frames those moves as freeing capital for reinvestment into higher-growth opportunities and reducing leverage that it sees as a constraint on strategic flexibility. FMC underscores that the review and balance-sheet work are complementary steps to reshape the company around its most competitive assets.

FMC highlights four recently developed active ingredients — Isoflex® active, fluindapyr, Dodhylex® active and rimisoxafen — and a broader development pipeline as the focal point for potential acceleration. Management describes these actives as unique and potentially transformative, saying they could benefit from additional investment to accelerate commercialization and scale. At the same time, the company is prioritizing actions to improve the competitiveness of its legacy portfolio and to manage the post-patent transition for its key insecticide Rynaxypyr®.

2026 outlook and product headwinds

For full-year 2026 FMC provides revenue guidance of $3.60 billion to $3.80 billion, implying a midpoint decline of roughly 5% versus the prior year. The company says pricing is expected to be lower by mid-single digits, driven mainly by the post-patent dynamics for Rynaxypyr®, and signals that near-term top-line pressure is part of an anticipated transition as new actives are commercialized.

Communications and process

Chairman, CEO and President Pierre Brondeau says the company will pursue its operational priorities while the board explores strategic alternatives, reiterating that there is no assurance the review will lead to any transaction. FMC plans to discuss results further on an upcoming earnings call and does not intend further comment at this time unless additional disclosure becomes appropriate.